Project 1: Opposing Roles of Wild-type and Mutant p53 in Regulating Oncogenesis. The wild-type p53 protein is recognized as a major tumor suppressor protein. p53 sits at the hub of numerous upstream stress signaling and downstream gene regulatory pathways and works as a transcription factor whose varied transcriptional targets mediate numerous cellular outcomes. Depending on the context, these include cell cycle, cell death, senescence, metabolic changes and others that serve to protect cells from acquiring cancerous properties. By contrast, evidence continues to mount that the common mutant forms of p53 found in human tumors are actually contributing to their malignant properties. Both wild-type and mutant p53 have been shown to regulate expression over 1000 genes each. Interestingly, in many cases the genes and pathways that mutant p53 upregulates are actively inhibited by wild-type p53. One line of evidence for mutant p53 gain of oncogenic function that was supported by this program was the discovery that mutant p53 regulates the SREBP-2-dependent mevalonic acid (MVA) pathway by which cells synthesize cholesterol and that this is required for the malignant characteristics of breast cancer cells grown in 3D cultures. We now have evidence in collaboration with the Lowe laboratory that wild-type p53 actively represses the MVA pathway by a novel mechanism whereby p53 induces the ABCA1 cholesterol exporter leading to blocked maturation of the SREBP-2 transcription factor. With Scott Lowe we showed that p53 repression of the MVA pathway is required for Myc/p53 null liver tumors to develop. Interestingly, a key byproduct of the MVA pathway, namely protein geranylgeranylation, is required for mutant p53 to upregulate the MVA pathway and ablation of this byproduct plays a role in wild-type repression of this pathway. We also recently discovered VEGFR2, the receptor for the pro-angiogenic VEGF ligand, as another gene that is up-regulated by mutant p53 in breast cancer cells. Activation of VEGFR2 RNA expression involves mutant p53 cooperation with the SWI/SNF chromatin remodeling complex. Indeed, mutant p53 regulation of nearly half of its targets including the MVA pathway genes requires SWI/SNF. The goals of this project are to gain further insight into how mutant p53 works with SREBP2 to regulate both known (MVA and VEGFR2) as well as anticipated new target genes, to gain insight into the positive feedback relationship between mutant p53 and SWI/SNF, to determine how and when p53 activates ABCA1 to block maturation of the SREBP2 protein, to identify which geranylgeranyl targets are required for maintaining growth and malignancy in breast cancer cell cultures, and to identify factors that lead to dependency on the MVA pathway for viability. These experiments, which will potentially inform new treatments for cancer, will in many cases involve collaborative projects with the other members of this program.

Public Health Relevance

The gene encoding the p53 protein is frequently mutated in many forms of human cancer. It is well established that the normal form of p53 serves many functions to protect cells, animals and humans from acquiring tumors, thereby defining p53 as an important suppressor of tumor formation. Some of the mutated forms of p53 found in tumors serve the opposite function in that they actually promote cancerous behavior of cells. The basis for many of the experiments in this project are to determine how cancer related mutant forms of p53 stimulate expression of the mevalonate pathway by which cells make cholesterol and key byproducts, and how the normal wild-type form of p53 actually dampens this same pathway. Results from the planned experiments could refine treatment options for breast cancer patients and might also contribute to novel therapies for liver cancer patients for whom there are currently no effective treatments.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA087497-16A1
Application #
9281455
Study Section
Special Emphasis Panel (ZCA1-RPRB-O (J1))
Project Start
Project End
Budget Start
2017-04-01
Budget End
2018-03-31
Support Year
16
Fiscal Year
2017
Total Cost
$338,838
Indirect Cost
$127,064
Name
Columbia University (N.Y.)
Department
Type
Domestic Higher Education
DUNS #
049179401
City
New York
State
NY
Country
United States
Zip Code
10027
Hirschhorn, Tal; Stockwell, Brent R (2018) The development of the concept of ferroptosis. Free Radic Biol Med :
Liu, Hengrui; Schreiber, Stuart L; Stockwell, Brent R (2018) Targeting Dependency on the GPX4 Lipid Peroxide Repair Pathway for Cancer Therapy. Biochemistry 57:2059-2060
Conrad, Marcus; Kagan, Valerian E; Bayir, Hülya et al. (2018) Regulation of lipid peroxidation and ferroptosis in diverse species. Genes Dev 32:602-619
Zhang, Yan; Larraufie, Marie-Hélène; Musavi, Leila et al. (2018) Design of Small Molecules That Compete with Nucleotide Binding to an Engineered Oncogenic KRAS Allele. Biochemistry 57:1380-1389
Shimada, Kenichi; Reznik, Eduard; Stokes, Michael E et al. (2018) Copper-Binding Small Molecule Induces Oxidative Stress and Cell-Cycle Arrest in Glioblastoma-Patient-Derived Cells. Cell Chem Biol 25:585-594.e7
Gaschler, Michael M; Andia, Alexander A; Liu, Hengrui et al. (2018) FINO2 initiates ferroptosis through GPX4 inactivation and iron oxidation. Nat Chem Biol 14:507-515
Morris, Dylan H; Gostic, Katelyn M; Pompei, Simone et al. (2018) Predictive Modeling of Influenza Shows the Promise of Applied Evolutionary Biology. Trends Microbiol 26:102-118
Solovyov, Alexander; Vabret, Nicolas; Arora, Kshitij S et al. (2018) Global Cancer Transcriptome Quantifies Repeat Element Polarization between Immunotherapy Responsive and T Cell Suppressive Classes. Cell Rep 23:512-521
Gaschler, Michael M; Hu, Fanghao; Feng, Huizhong et al. (2018) Determination of the Subcellular Localization and Mechanism of Action of Ferrostatins in Suppressing Ferroptosis. ACS Chem Biol 13:1013-1020
Rokudai, Susumu; Li, Yingchun; Otaka, Yukihiro et al. (2018) STXBP4 regulates APC/C-mediated p63 turnover and drives squamous cell carcinogenesis. Proc Natl Acad Sci U S A 115:E4806-E4814

Showing the most recent 10 out of 159 publications